| Methods |
RCT, 1992‐97, concealed allocation |
| Participants |
205 patients randomised, age >60
stage II‐IV high‐grade NHL, untreated |
| Interventions |
CHOP with G‐CSF versus CHOP without G‐CSF
1. CT:
Cyclophosphamide 750 mg/m², iv, d1
Vincristine 1.4 mg/m², iv, d1
Doxorubicin 50 mg/m², iv, d1
Prednisone 100 mg/m², po, d1‐5
2. G‐CSF (5 µg/kg/day, sc, d2‐d10/14)
3. no placebo given*
4. no AB prophylaxis given* |
| Outcomes |
toxicity (severe neutropenia, infections), tumour response, survival |
| Notes |
funding: Roche, Amgen, Wyeth Lederle and the Swedish Cancer Society |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
